Zepbound®

What Zepbound® Is and How It Works

Zepbound® (tirzepatide) is a once-weekly, single-dose injection for chronic weight management in adults with obesity or overweight and at least one related health condition. It activates both GIP and GLP-1 receptors. This dual action helps reduce appetite, support smaller portions, and improve metabolic measures when used with a reduced-calorie diet and increased physical activity.

Tirzepatide is supplied as single-use, prefilled pens in multiple strengths. Typical strengths include 2.5 mg/0.5 mL, 5 mg/0.5 mL, 7.5 mg/0.5 mL, 10 mg/0.5 mL, 12.5 mg/0.5 mL, and 15 mg/0.5 mL. Pens are discarded after one injection. Treatment is titrated stepwise to improve tolerability.

Dosage and Usage

Use Zepbound as directed by your prescriber. General dosing follows a step-up schedule to help limit stomach-related side effects.

• Start: 2.5 mg once weekly for 4 weeks.
• Increase: 5 mg once weekly for at least 4 weeks.
• Further increases: 7.5 mg, then 10 mg, 12.5 mg, and 15 mg once weekly as tolerated.
• Inject on the same day each week, any time of day, with or without meals.
• Rotate injection sites: abdomen, thigh, or back of upper arm.
• Use a new pen for each dose; do not reuse or share pens.
• Missed dose: If within 4 days (96 hours) of the missed dose, take it as soon as possible. If more than 4 days have passed, skip the dose and take the next dose on the regular day.
• Changing dose day: You may change the weekly day if the time between doses is at least 3 days (72 hours).
• Injection steps (general): Wash hands, check the pen label and expiration date, clean the skin, unlock the pen, press and hold against the skin until the injection is complete per device instructions, then dispose of safely in a sharps container.

Storage and Travel

• Refrigerate unopened pens at 2–8 °C (36–46 °F). Do not freeze; discard if frozen.
• Protect from light; keep pens in the original carton.
• Room temperature: Unopened pens may be kept up to 30 °C (86 °F) for up to 21 days. Do not return to the refrigerator once kept at room temperature.
• Do not shake pens.
• Travel: Use an insulated bag with gel packs. Keep pens with you, not in checked luggage.
• Dispose of used pens and needles in an FDA-cleared sharps container.

Benefits

Tirzepatide’s dual GIP/GLP-1 mechanism supports meaningful weight loss when combined with diet and activity. Many people notice reduced hunger, smaller portions, and steadier eating patterns. Weekly dosing offers simplicity, and single-use pens limit handling complexity.

Side Effects and Safety

• Nausea, vomiting, or diarrhoea
• Constipation
• Abdominal discomfort or pain
• Decreased appetite
• Indigestion or reflux
• Belching, gas, or bloating
• Fatigue
• Injection site redness or itching
• Dizziness or headache

Serious risks are uncommon but can include pancreatitis, gallbladder problems (such as gallstones), and kidney issues related to dehydration. Tirzepatide carries a boxed warning for risk of thyroid C-cell tumours; do not use if you or family members have a history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2). Hypoglycaemia can occur when tirzepatide is used with insulin or sulfonylureas; dose adjustments may be needed. Use is not recommended during pregnancy.

Onset Time

Appetite effects may begin in the first 1–2 weeks at the starting dose. As titration continues, many patients see steadier appetite control and smaller portions. Weight changes are usually gradual. Early loss can appear by weeks 4–8, with more visible changes after 8–12 weeks at a maintenance dose. Results typically build over several months alongside lifestyle changes.

Compare With Alternatives

Wegovy® (semaglutide): a once-weekly GLP-1 receptor agonist approved for chronic weight management, typically at a fixed 2.4 mg dose.

Mounjaro® (tirzepatide): approved for type 2 diabetes; contains the same active ingredient as Zepbound, but is labelled for diabetes management rather than obesity.

Rybelsus® (oral semaglutide): a tablet taken daily for type 2 diabetes. Not indicated for weight management, but may suit patients who prefer oral therapy.

Combination Therapy

• Metformin: commonly continued in those with type 2 diabetes.
• SGLT2 inhibitors: may be combined; monitor hydration and kidney function.
• Statins and antihypertensives: often continued for cardiometabolic risk management.
• Insulin or sulfonylureas: doses may need reducing to lower hypoglycaemia risk.
• Do not combine with other GLP-1 receptor agonists.

Patient Suitability

Candidates include adults with BMI ≥30 kg/m², or ≥27 kg/m² with at least one weight-related condition such as hypertension, dyslipidaemia, obstructive sleep apnoea, or type 2 diabetes. Zepbound is not for people with a personal or family history of MTC or MEN 2, during pregnancy, or for those with serious hypersensitivity to tirzepatide.

Use caution in patients with a history of pancreatitis, gallbladder disease, severe gastrointestinal disease, diabetic retinopathy, or kidney impairment. Report persistent or severe GI symptoms, vision changes, or signs of pancreatitis promptly to a healthcare professional.

Authoritative Sources

Zepbound (tirzepatide) U.S. Prescribing Information – Eli Lilly

FDA Labeling and Medication Guide for Tirzepatide (Zepbound)

Official Zepbound Patient Site – Eli Lilly

This page is for educational purposes and does not replace advice from your healthcare professional. Always follow your prescriber’s directions and the official medication guide.